Trial Profile
Answering question on tolvaptan's efficacy for patients with acute decompensated heart failure and renal failure: AQUAMARINE Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2016
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Furosemide
- Indications Decompensated heart failure; Heart failure; Renal failure
- Focus Therapeutic Use
- Acronyms AQUAMARINE
- 16 Nov 2016 Results of secondary analysis (n=184) assessing the prognostic influence of the sodium level trajectory (sodium dipping vs. nonsodium-dipping group) in acute heart failure patients, presented at the 89th Annual Scientific Sessions of the American Heart Association.
- 01 Feb 2014 Trial design presented at Cardiovascular Drugs & Therapy.
- 26 Jan 2012 New trial record